Eylea approved for AMD eye disorder in older people
Regeneron Announces FDA Approval of EYLEA? (Aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration – The U.S. Food and Drug Administration approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.